The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Transcript
What are some of the biggest challenges in the treatment landscape of neuroendocrine tumors currently?
I think that the biggest challenge that we have now is really how to sequence all of these therapies. To start, if you can cut them out, cut them out. But, when you’re at a point that you’re having to use medical therapies, the biggest confusion we have now is we’ve got a whole mix of different things to use and we’re really not sure of the right sequencing for it and how to pick the right patient to sequence those treatments.
In other words, say pancreatic neuroendocrine tumors [NETs]. Should we be using capecitabine and temozolomide before we should be using peptide receptor radionuclide therapy [PRRT], or vice versa? Those decisions, we really don’t have a lot of information. We’ve had a lot of new drugs come in and not a lot of information on how to take a patient through that entire treatment algorithm.
I usually tell patients they’re going to see every treatment we can get to them, but what’s the most optimal strategy for taking them 1, 2, 3, 4, 5 through that regimen is not really known. So, I think that’s a big challenge.
I think the intermediate high-grade or the well-differentiated G3, which is kind of the new pathologic assessment of these tumors is a challenging group. We don’t know if chemotherapy serves those patients best or if they’re better served with things like PRRT, and there was certainly a spirited debate about that this morning. I don’t think that question is really answered, and that treatment needs to be individualized and it often leaves a lot of hand ringing for the oncologist.
I think the final biggest challenge is lung. I think lung has had a lot of disservice in a lot of different clinical trials. So, we’re starting to see a lot more focus on lung NETs as a specific entity and hopefully get a little more data so we know what we’re doing in that setting.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More